{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:09:34Z","timestamp":1793376574813,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["Clinical Medicine Plus X -Young Scholars Project, Peking University, the Fundamental Research Funds for the Central Universities"],"award-info":[{"award-number":["Clinical Medicine Plus X -Young Scholars Project, Peking University, the Fundamental Research Funds for the Central Universities"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate efficacy and safety of ceftazidime-avibactam (CZA) in preterm infants with multidrug-resistant (MDR) or extensive drug-resistant (XDR) bacterial infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Retrospective analysis of clinical data was conducted on preterm infants who were monitored in NICU of Peking University of First Hospital for MDR\/XDR infections between 2022 and 2025. A literature search was performed using PUBMED and WANFANG databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six preterm infants (median gestational age 26\n                      <jats:sup>+3<\/jats:sup>\n                      weeks) received CZA treatment for MDR\/XDR bacterial infections, including five bloodstream infections and one ventilator associated pneumonia. CZA was used as monotherapy in three patients and as combination therapy with colistin or aztreonam in three patients. The median postnatal age at treatment initiation was 31 days. Five patients achieved clinical cure without adverse effects (AEs). One patient with concurrent CNS infection did not complete the treatment due to onset of unexpected status epilepticus. The literature search retrieved 44 preterm infants or neonates using CZA for sepsis or focal infections. Clinical cure rate was 84.09% (37\/44). The most frequent AEs included liver function abnormalities, increased serum creatinine, hypomagnesemia and thrombocytopenia which were reversible.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CZA alone or combined with aztreonam or colistin is effective and well-tolerated in critically ill preterm infants. However, the small sample size of patients limits the definitive conclusions about the safety profile of CZA, especially CNS risks. Further studies on the pharmacokinetics\/pharmacodynamics and safety of CZA in preterm infants are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1723315","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:27:34Z","timestamp":1765780054000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ceftazidime-avibactam for the treatment of multidrug-resistant or extensively drug-resistant bacteria infection in preterm infants: case series study and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Shiqi","family":"Guang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifang","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/antibiotics11081088","article-title":"Therapeutic options and outcomes for the treatment of neonates and preterms with gram-negative multidrug-resistant Bacteria: a systematic review","volume":"11","author":"Chiusaroli","year":"2022","journal-title":"Antibiotics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/inf.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to 18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"piaf028","DOI":"10.1093\/jpids\/piaf028","article-title":"Pharmacokinetics and safety of ceftazidime-avibactam in neonates and young infants: a phase 2a, multicenter prospective trial","volume":"14","author":"Bradley","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1016\/s2214-109x(16)30148-6","article-title":"Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study","volume":"4","author":"Chaurasia","year":"2016","journal-title":"Lancet Glob Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.2147\/idr.S416020","article-title":"Prevalence of multidrug-resistant pathogens causing neonatal early and late onset sepsis, a retrospective study from the tertiary referral Children\u2019s hospital","volume":"16","author":"Fang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12887-024-04639-9","article-title":"Risk factors of multidrug-resistant organisms neonatal sepsis in surabaya tertiary referral hospital: a single-center study","volume":"24","author":"Miranda","year":"2024","journal-title":"BMC Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.meegid.2014.11.025","article-title":"Evaluation of carbapenem-resistant Enterobacteriaceae in an Italian setting: report from the trench","volume":"30","author":"Barbarini","year":"2015","journal-title":"Infect Genet Evol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.23736\/s0375-9393.19.13521-3","article-title":"Ceftazidine-avibactam salvage therapy in newborn with KPC-producing Klebsiella pneumoniae invasive infections","volume":"85","author":"Esposito","year":"2019","journal-title":"Minerva Anestesiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/inf.0000000000002344","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/inf.0000000000002807","article-title":"Successful treatment of pandrug-resistant Klebsiella pneumoniae infection with ceftazidime-avibactam in a preterm infant: a case report","volume":"39","author":"Coskun","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/08971900221087131","article-title":"Off-label use of ceftazidime-avibactam in a premature infant with multidrug-resistant Klebsiella pneumoniae infection: a case report","volume":"36","author":"Nascimento","year":"2023","journal-title":"J Pharm Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5863\/1551-6776-27.2.192","article-title":"Intravenous ceftazidime-avibactam in extremely premature neonates with carbapenem-resistant enterobacteriaceae: two case reports","volume":"27","author":"Asfour","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/antibiotics12081302","article-title":"Off-label use of ceftazidime\/avibactam for the treatment of pan-drug-resistant Klebsiella pneumoniae in a neonate. Case report and literature review","volume":"12","author":"Mangarov","year":"2023","journal-title":"Antibiotics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/antibiotics12071169","article-title":"Ceftazidime-avibactam treatment for Klebsiella pneumoniae bacteremia in preterm infants in NICU: a clinical experience","volume":"12","author":"Marino","year":"2023","journal-title":"Antibiotics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/inf.0000000000004092","article-title":"Carbapenem-resistant Klebsiella pneumoniae osteoarthritis in two preterm infants treated with ceftazidime-avibactam","volume":"42","author":"Pu","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/inf.0000000000004247","article-title":"Off-label use of ceftazidime\/avibactam in neonatal intensive care unit: a real-life experience and literature review","volume":"43","author":"Ftergioti","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"B19","first-page":"2304","article-title":"\u8042\u96ea\u5764","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12941-023-00660-5","article-title":"Comparison of the inoculum effect of in vitro antibacterial activity of imipenem\/relebactam and ceftazidime\/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae","volume":"22","author":"Wang","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1503.e1","DOI":"10.1016\/j.cmi.2022.06.018","article-title":"Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales","volume":"28","author":"Danjean","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.2147\/idr.S469313","article-title":"Adequacy of the dosing and infusion time of ceftazidime\/avibactam for the treatment of gram-negative bacterial infections: a PK\/PD simulation study","volume":"17","author":"Han","year":"2024","journal-title":"Infect Drug Resist"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e00779","DOI":"10.1128\/aac.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s12879-023-08715-w","article-title":"Ceftazidime\/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant gram-negative bacilli infection","volume":"23","author":"Zheng","year":"2023","journal-title":"BMC Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1011723","DOI":"10.3389\/fped.2023.1011723","article-title":"Metagenomics by next-generation sequencing (mNGS) in the etiological characterization of neonatal and pediatric sepsis: a systematic review","volume":"11","author":"Agudelo-P\u00e9rez","year":"2023","journal-title":"Front Pediatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"155207","DOI":"10.1016\/j.jcrc.2025.155207","article-title":"Ceftazidime-avibactam plus aztreonam for extensively drug-resistant gram-negative infections in critically ill patients","volume":"90","author":"Biswal","year":"2025","journal-title":"J Crit Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1086\/302205","article-title":"Rapid clearance of fetal DNA from maternal plasma","volume":"64","author":"Lo","year":"1999","journal-title":"Am J Hum Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/microorganisms11030627","article-title":"From gut to blood: spatial and temporal pathobiome dynamics during acute abdominal murine sepsis","volume":"11","author":"Hartwig","year":"2023","journal-title":"Microorganisms"},{"key":"B30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-0716-3291-8_11","article-title":"NGS-based tumor-informed analysis of circulating tumor DNA","volume":"2684","author":"Nordentoft","year":"2023","journal-title":"Methods Mol Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"106395","DOI":"10.1016\/j.jinf.2024.106395","article-title":"Diagnostic performance of metagenomic next-generation sequencing among hematological malignancy patients with bloodstream infections after antimicrobial therapy","volume":"90","author":"Xu","year":"2025","journal-title":"J Infect"},{"key":"B32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.seizure.2020.08.012","article-title":"Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations","volume":"81","author":"Wanleenuwat","year":"2020","journal-title":"Seizure"},{"key":"B33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4103\/0259-1162.159773","article-title":"Convulsions following rapid ceftazidime administration for preinduction antibiotic prophylaxis during neurosurgical procedure","volume":"9","author":"Haldar","year":"2015","journal-title":"Anesth Essays Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/jcpt.13796","article-title":"Central nervous system adverse events of ceftazidime\/avibactam: a retrospective study using food and drug administration adverse event reporting system","volume":"47","author":"Guo","year":"2022","journal-title":"J Clin Pharm Ther"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1723315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:27:36Z","timestamp":1765780056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1723315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":34,"alternative-id":["10.3389\/fped.2025.1723315"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1723315","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1723315"}}